In addition, S1P regulation via SPL inhibition has been demonstrated to enhance bone mass and strength in a S1PR2-dependant manner in vivo, which also effectively ameliorating osteoporosis in S1PR2-deficient mice, suggesting S1P is a potential therapeutic target for bone diseases (28). The gene discussed is S1PR2; the disease is osteoporosis.